The 2 AM Reality
It is 2 AM at the hospital. I am processing an admission for “Mr. B,” a 70 year old with COPD. This is his second admission of 2026, and March has just begun. Mr. B is the “Gold Standard” failure: he is adherent to triple therapy (ICS/LAMA/LABA) and uses his rescue inhaler religiously. Yet, he is back in a hospital bed.
As a busy hospitalist, I often bear witness to a revolving door of patients who are maxed out on current therapies. My spidey sense tells me that Wall Street sees a crowded market of COPD medications. I see a massive unmet need..
The Data: BOREAS and the Type 2 Signal
The BOREAS trial (NEJM) recently validated what many of us suspected: COPD isn’t a monolithic disease. While traditionally viewed as a neutrophilic disease of smokers, roughly 30-40% of patients exhibit Type 2 (eosinophilic) inflammation.
Enter Dupilumab (Regeneron/Sanofi). By inhibiting the IL-4 and IL-13 pathways, Dupilumab doesn’t just treat symptoms; it modifies the inflammatory driver. The results were binary:
- 30% reduction in moderate-to-severe exacerbations.
- Significant FEV1 improvement (lung function).
- A “clean” safety profile with adverse events that were similar to placebo, meaning we aren’t making sick people sicker.
The “Alpha” is in the AEC
For the price of a cup of coffee (a standard CBC with differential), we can identify these patients. An Absolute Eosinophil Count (AEC) > 300 is the “genetic marker” the market is ignoring. These patients are “gold nuggets” discarded by a system that prioritizes the cost of the drug over the cost of the bed.
Currently, AEC is not a routine part of the COPD workup for many PCPs or even Pulmonologists. This creates a massive, undiagnosed pool of candidates for Dupilumab that the market has yet to price in.
The “Tail Wagging the Dog”
The 2026 GOLD guidelines still view biologics as a last resort. This is the “house burning down” strategy: we wait for the patient to accumulate permanent lung damage and five-figure hospital bills before we turn on the “biologic sprinkler system.”
Insurance red tape remains the primary hurdle, but the math is becoming undeniable. If a $3,000/month drug prevents a $20,000 admission every 60 days, the “price tag” argument collapses under the weight of actuarial reality.
The Verdict
Every COPD patient needs a stable state AEC check as a matter of protocol. Those > 300 aren’t just “severe COPDers” but they are Type 2 patients trapped in a Type 1 treatment model. For REGN/Sanofi, the growth isn’t just in the drug; it’s in the inevitable shift toward precision medicine in the most expensive ward of the hospital.
Clinical Composite: The patient case of “Mr. B” described in this post is a fictional composite created for educational and illustrative purposes. Any resemblance to actual persons, living or deceased, is purely coincidental. This analysis reflects the author’s personal clinical perspective on published medical literature and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition.
Professional & Financial Disclosure: The views expressed here are my own and do not necessarily reflect the views of my employer or affiliated institutions. At the time of writing, the author holds no financial position in Regeneron (REGN) or Sanofi (SNY). This post is for informational purposes and is not intended as investment advice.